Literature DB >> 18350371

Prnp knockdown in transgenic mice using RNA interference.

Micaela Gallozzi1, Jérome Chapuis, Fabienne Le Provost, Annick Le Dur, Caroline Morgenthaler, Coralie Peyre, Nathalie Daniel-Carlier, Eric Pailhoux, Marthe Vilotte, Bruno Passet, Laetitia Herzog, Vincent Beringue, José Costa, Philippe Tixador, Gaëlle Tilly, Hubert Laude, Jean-Luc Vilotte.   

Abstract

RNA interference has become a widely used approach to perform gene knockdown experiments in cell cultures and more recently transgenic animals. A designed miRNA targeting the prion protein mRNA was built and expressed using the human PRNP promoter. Its efficiency was confirmed in transfected cells and it was used to generate several transgenic mouse lines. Although expressed at low levels, it was found to downregulate the endogenous mouse Prnp gene expression to an extent that appears to be directly related with the transgene expression level and that could reach up to 80% inhibition. This result highlights the potential and limitations of the RNA interference approach when applied to disease resistance.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350371     DOI: 10.1007/s11248-008-9179-2

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  59 in total

1.  Transmission of prions.

Authors:  C Weissmann; M Enari; P-C Klöhn; D Rossi; E Flechsig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

2.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

3.  Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice.

Authors:  Alexander Pfeifer; Sabina Eigenbrod; Saba Al-Khadra; Andreas Hofmann; Gerda Mitteregger; Markus Moser; Uwe Bertsch; Hans Kretzschmar
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

4.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

5.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

6.  Cultured peripheral neuroglial cells are highly permissive to sheep prion infection.

Authors:  Fabienne Archer; Corinne Bachelin; Olivier Andreoletti; Nathalie Besnard; Gregory Perrot; Christelle Langevin; Annick Le Dur; Didier Vilette; Anne Baron-Van Evercooren; Jean-Luc Vilotte; Hubert Laude
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

7.  Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein.

Authors:  H Büeler; M Fischer; Y Lang; H Bluethmann; H P Lipp; S J DeArmond; S B Prusiner; M Aguet; C Weissmann
Journal:  Nature       Date:  1992-04-16       Impact factor: 49.962

8.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs.

Authors:  Nathalie Daude; Mathieu Marella; Joelle Chabry
Journal:  J Cell Sci       Date:  2003-05-20       Impact factor: 5.285

9.  Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.

Authors:  M Fischer; T Rülicke; A Raeber; A Sailer; M Moser; B Oesch; S Brandner; A Aguzzi; C Weissmann
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

10.  Tolerated wobble mutations in siRNAs decrease specificity, but can enhance activity in vivo.

Authors:  Torgeir Holen; Svein Erik Moe; Jan Gunnar Sørbø; Trine J Meza; Ole Petter Ottersen; Arne Klungland
Journal:  Nucleic Acids Res       Date:  2005-08-19       Impact factor: 16.971

View more
  7 in total

Review 1.  MicroRNAs as a molecular basis for mental retardation, Alzheimer's and prion diseases.

Authors:  Patrick Provost
Journal:  Brain Res       Date:  2010-03-27       Impact factor: 3.252

2.  Combination of the somatic cell nuclear transfer method and RNAi technology for the production of a prion gene-knockdown calf using plasmid vectors harboring the U6 or tRNA promoter.

Authors:  Pimprapar Wongsrikeao; Shizuyo Sutou; Miho Kunishi; Ya Juan Dong; Xuejin Bai; Takeshige Otoi
Journal:  Prion       Date:  2011-01-01       Impact factor: 3.931

3.  Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures.

Authors:  Bruce Pulford; Natalia Reim; Aimee Bell; Jessica Veatch; Genevieve Forster; Heather Bender; Crystal Meyerett; Scott Hafeman; Brady Michel; Theodore Johnson; A Christy Wyckoff; Gino Miele; Christian Julius; Jan Kranich; Alan Schenkel; Steven Dow; Mark D Zabel
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

4.  Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes.

Authors:  Heather R Bender; Sarah Kane; Mark D Zabel
Journal:  J Vis Exp       Date:  2016-07-23       Impact factor: 1.355

5.  Knockdown of the prion gene expression by RNA interference in bovine fibroblast cells.

Authors:  Shaohua Wang; Xiaoqing Lv; Kun Zhang; Tonghui Lin; Xiaofang Liu; Jing Yuan; Yunping Dai; Ning Li
Journal:  Mol Biol Rep       Date:  2009-10-11       Impact factor: 2.316

Review 6.  Progress on RNAi-based molecular medicines.

Authors:  Jing Chen; Jianping Xie
Journal:  Int J Nanomedicine       Date:  2012-07-26

Review 7.  MicroRNAs in Prion Diseases-From Molecular Mechanisms to Insights in Translational Medicine.

Authors:  Danyel Fernandes Contiliani; Yasmin de Araújo Ribeiro; Vitor Nolasco de Moraes; Tiago Campos Pereira
Journal:  Cells       Date:  2021-06-29       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.